• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

第二种肽增强肽抗原呈递

Enhancement of peptide antigen presentation by a second peptide.

作者信息

de Kroon A I, McConnell H M

机构信息

Department of Chemistry, Stanford University, CA 94305.

出版信息

Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8797-801. doi: 10.1073/pnas.90.19.8797.

DOI:10.1073/pnas.90.19.8797
PMID:8105466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC47447/
Abstract

The influence of nonstimulatory "competitor" peptides on the binding of an antigenic peptide to a major histocompatibility complex (MHC) class II molecule was investigated. Using high-performance size-exclusion chromatography and fluorescein-labeled peptides, we show that the presence of the peptides dynorphin A-(1-13) and poly(L-lysine) results in enhancement rather than inhibition of the binding of hen egg lysozyme peptide-(107-116) [HEL-(107-116)] to the detergent-solubilized mouse class II molecule IEd. In parallel, dynorphin A-(1-13) and poly(L-lysine) were found to enhance the specific activation of an IEd-restricted T-cell hybridoma by HEL-(107-116). A molecular mechanism involving an intermediate two peptide-MHC class II protein complex is proposed to explain the enhancement of peptide binding to class II molecules by an irrelevant second peptide.

摘要

研究了非刺激性“竞争”肽对抗原肽与主要组织相容性复合体(MHC)II类分子结合的影响。使用高效尺寸排阻色谱法和荧光素标记的肽,我们发现强啡肽A-(1-13)和聚(L-赖氨酸)肽的存在导致溶菌酶肽-(107-116)[HEL-(107-116)]与去污剂溶解的小鼠II类分子IEd的结合增强而非抑制。同时,发现强啡肽A-(1-13)和聚(L-赖氨酸)可增强HEL-(107-116)对IEd限制性T细胞杂交瘤的特异性激活。提出了一种涉及中间双肽-MHC II类蛋白复合物的分子机制,以解释无关的第二种肽增强肽与II类分子结合的现象。

相似文献

1
Enhancement of peptide antigen presentation by a second peptide.第二种肽增强肽抗原呈递
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8797-801. doi: 10.1073/pnas.90.19.8797.
2
Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.通过给予主要组织相容性复合体(MHC)II类结合肽实现选择性免疫抑制。I. 体内MHC阻断预防T细胞活化的证据。
J Exp Med. 1992 May 1;175(5):1345-52. doi: 10.1084/jem.175.5.1345.
3
Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.将鸡卵溶菌酶靶向定位于胞质溶胶会产生一种由I类而非II类主要组织相容性复合体分子呈递的短寿命蛋白质。
Eur J Immunol. 1991 Mar;21(3):761-9. doi: 10.1002/eji.1830210332.
4
Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells.在MHC II类分子限制的T细胞激活过程中,同一肽与I-Ek和I-Ed分子相互作用的结构要求比较。
J Immunol. 1991 Jul 1;147(1):198-204.
5
Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells.外源性肽竞争将内源性抗原呈递给主要组织相容性复合体II类限制性T细胞。
J Exp Med. 1991 Oct 1;174(4):945-8. doi: 10.1084/jem.174.4.945.
6
Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing.与细胞内加工产生的复合物相比,游离肽与II类主要组织相容性复合体分子结合产生的复合物在抗原性上具有多样性。
J Immunol. 1996 Apr 1;156(7):2365-8.
7
Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses.通过给予主要组织相容性复合体II类结合肽实现选择性免疫抑制。II. 对体内初次和二次抗体应答的预防性抑制
J Exp Med. 1993 May 1;177(5):1461-8. doi: 10.1084/jem.177.5.1461.
8
Analysis of the interaction of peptide hen egg white lysozyme (34-45) with the I-Ak molecule.肽鸡卵清溶菌酶(34 - 45)与I - Ak分子相互作用的分析。
J Immunol. 1989 Aug 1;143(3):802-7.
9
Kinetics and specificity of peptide-MHC class II complex displacement reactions.肽 - 主要组织相容性复合体II类复合物置换反应的动力学和特异性
J Immunol. 1994 Jan 15;152(2):609-19.
10
Inhibition of T cell response with peptides is influenced by both peptide-binding specificity of major histocompatibility complex molecules and susceptibility of T cells to blocking.肽对T细胞反应的抑制受到主要组织相容性复合体分子的肽结合特异性和T细胞对阻断的敏感性的影响。
Eur J Immunol. 1989 Jun;19(6):1071-7. doi: 10.1002/eji.1830190617.

引用本文的文献

1
HLA-DM Focuses on Conformational Flexibility Around P1 Pocket to Catalyze Peptide Exchange.HLA-DM聚焦于P1口袋周围的构象灵活性以催化肽段交换。
Front Immunol. 2013 Oct 17;4:336. doi: 10.3389/fimmu.2013.00336.
2
HLA-DM: arbiter conformationis.HLA-DM:决定构象的仲裁者。
Immunology. 2013 Feb;138(2):85-92. doi: 10.1111/imm.12030.
3
Interpretation of biphasic dissociation kinetics for isomeric class II major histocompatibility complex-peptide complexes.对同种异型 II 类主要组织相容性复合物-肽复合物的双相解离动力学的解释。
Biophys J. 1999 Nov;77(5):2451-61. doi: 10.1016/S0006-3495(99)77081-5.
4
Catalysis of peptide dissociation from class II MHC-peptide complexes.催化肽从II类主要组织相容性复合体-肽复合物中解离。
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6581-6. doi: 10.1073/pnas.96.12.6581.
5
An insulin peptide that binds an alternative site in class II major histocompatibility complex.一种与II类主要组织相容性复合体中的替代位点结合的胰岛素肽。
J Exp Med. 1996 Mar 1;183(3):857-66. doi: 10.1084/jem.183.3.857.
6
Kinetic intermediates in the reactions between peptides and proteins of major histocompatibility complex class II.主要组织相容性复合体II类肽与蛋白质反应中的动力学中间体。
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8842-5. doi: 10.1073/pnas.91.19.8842.
7
Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH.在内体pH值下,从HLA - DR1分子中选择性释放一些恒定链衍生肽。
J Exp Med. 1994 Aug 1;180(2):751-5. doi: 10.1084/jem.180.2.751.
8
Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41.主要组织相容性复合体II类相关恒定链的蛋白水解由可变剪接基因产物p41调控。
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10257-61. doi: 10.1073/pnas.92.22.10257.

本文引用的文献

1
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.用于细胞生长和存活的快速比色测定法:应用于增殖和细胞毒性测定。
J Immunol Methods. 1983 Dec 16;65(1-2):55-63. doi: 10.1016/0022-1759(83)90303-4.
2
A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules.II类组织相容性分子的外来抗原结合位点的假设模型。
Nature. 1988 Apr 28;332(6167):845-50. doi: 10.1038/332845a0.
3
Autologous peptides constitutively occupy the antigen binding site on Ia.自体肽持续占据Ia上的抗原结合位点。
Science. 1988 Nov 18;242(4881):1045-7. doi: 10.1126/science.3194755.
4
Structural requirements for the interaction between peptide antigens and I-Ed molecules.肽抗原与I-Ed分子相互作用的结构要求。
J Immunol. 1989 Nov 15;143(10):3289-94.
5
Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule.独特型肽的最小长度及其与主要组织相容性复合体II类分子结合的模型。
EMBO J. 1989 Jul;8(7):1947-52. doi: 10.1002/j.1460-2075.1989.tb03599.x.
6
Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis.通过序列模式分析预测蛋白质抗原的主要组织相容性复合体结合区域
Proc Natl Acad Sci U S A. 1989 May;86(9):3296-300. doi: 10.1073/pnas.86.9.3296.
7
Analysis of peptide binding patterns in different major histocompatibility complex/T cell receptor complexes using pigeon cytochrome c-specific T cell hybridomas. Evidence that a single peptide binds major histocompatibility complex in different conformations.利用鸽细胞色素c特异性T细胞杂交瘤分析不同主要组织相容性复合体/T细胞受体复合物中的肽结合模式。单一肽以不同构象结合主要组织相容性复合体的证据。
J Exp Med. 1989 Nov 1;170(5):1609-25. doi: 10.1084/jem.170.5.1609.
8
A kinetic intermediate in the reaction of an antigenic peptide and I-Ek.一种抗原肽与I-Ek反应中的动力学中间体。
Nature. 1989 Jan 19;337(6204):274-6. doi: 10.1038/337274a0.
9
Interaction of an immunodominant epitope with Ia molecules in T-cell activation.免疫显性表位与Ia分子在T细胞活化中的相互作用。
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5181-5. doi: 10.1073/pnas.85.14.5181.
10
Analysis of physical interactions between peptides and HLA molecules and application to the detection of human immunodeficiency virus 1 antigenic peptides.肽与HLA分子之间物理相互作用的分析及其在人类免疫缺陷病毒1抗原肽检测中的应用。
J Exp Med. 1990 Sep 1;172(3):889-99. doi: 10.1084/jem.172.3.889.